Sustainability Report 2015 Lek d.d.

3 Lek, a pharmaceutical company, is one of the key pillars of Sandoz, the generic pharmaceuticals division of Novartis, a pioneer in the field of biosimilar medicinal products and world’s second largest generics pharma- ceuticals company. 849.4 mio EUR sales net income in 2015 or 11.6% more than in 2014 1.7 mrd EUR of Novartis’ investments in Slovenia in 13 years 88% proportion of senior management hired from the local community + 8% employees at the end of 2015 - 45% improved LTIR index, showing the rate of accidents, resulting in absence from work or the use of sick leave, reached the value of 0.12. - 5% reduced emissions of volatile organic compounds 3.2 mio EUR investment in environmental protection 14.7 TJ energy saved by energy efficiency improvement projectst + 10% improved water use efficiency 2015 KEY FACTS